Gene therapy for type 1 diabetes - Is it ready for the clinic?

被引：6

作者：

D'Anneo, Antonella

Rood, Pleunie

Bottino, Rita

Balamurugan, A. N.

He, Jing

Giannoukakis, Nick

机构：

[1] Univ Pittsburgh, Sch Med, Dept Pathol, Inst Diabet,Rangos Res Ctr, Pittsburgh, PA 15213 USA

[2] Childrens Hosp Pittsburgh, Inst Diabet, Pittsburgh, PA USA

[3] Univ Pittsburgh, Sch Med, Dept Pediat, Div Immunogenet, Pittsburgh, PA 15261 USA

[4] Univ Palermo, Dept Biochem Sci, Palermo, Italy

来源：

IMMUNOLOGIC RESEARCH | 2006年 / 36卷 / 1-3期

关键词：

diabetes; gene therapy; immunotherapy; autoimmunity;

D O I：

10.1385/IR:36:1:83

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 [免疫学];

摘要：

This review, in addition to updating the growing list of type I diabetes-relevant gene therapies, offers an outline of short-term objectives that can readily be met to move, at least, adenoviral and adeno-associated viral-based protocols into the clinic, first as a means of facilitating islet allografts as well as platforms with which to introduce immunoregulatory transgenes. A wide array of genes have been tested to restore insulin production, to drive the differentiation of insulin-producing progenitors, and to confer immunosuppression in an antigen- and tissue-restricted manner.

引用

页码：83 / 89

页数：7

共 62 条

[1]

In vivo gene transfer to healthy and diabetic canine pancreas [J].